190 related articles for article (PubMed ID: 34092057)
41. Telomeres and prognosis in patients with chronic lymphocytic leukaemia.
Sellmann L; de Beer D; Bartels M; Opalka B; Nückel H; Dührsen U; Dürig J; Seifert M; Siemer D; Küppers R; Baerlocher GM; Röth A
Int J Hematol; 2011 Jan; 93(1):74-82. PubMed ID: 21203871
[TBL] [Abstract][Full Text] [Related]
42. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
43. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
[TBL] [Abstract][Full Text] [Related]
44. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
45. Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia.
Hamblin TJ
Leuk Res; 2011 Nov; 35(11):1432-5. PubMed ID: 21840049
[TBL] [Abstract][Full Text] [Related]
46. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.
MacIntyre DA; Jiménez B; Lewintre EJ; Martín CR; Schäfer H; Ballesteros CG; Mayans JR; Spraul M; García-Conde J; Pineda-Lucena A
Leukemia; 2010 Apr; 24(4):788-97. PubMed ID: 20090781
[TBL] [Abstract][Full Text] [Related]
47. Use of IGHJ and IGHD gene mutations in analysis of immunoglobulin sequences for the prognosis of chronic lymphocytic leukemia.
Lee CE; Jackson KJ; Sewell WA; Collins AM
Leuk Res; 2007 Sep; 31(9):1247-52. PubMed ID: 17169423
[TBL] [Abstract][Full Text] [Related]
48. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles.
Kanduri M; Marincevic M; Halldórsdóttir AM; Mansouri L; Junevik K; Ntoufa S; Kultima HG; Isaksson A; Juliusson G; Andersson PO; Ehrencrona H; Stamatopoulos K; Rosenquist R
Epigenetics; 2012 Dec; 7(12):1435-42. PubMed ID: 23154584
[TBL] [Abstract][Full Text] [Related]
49. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
[TBL] [Abstract][Full Text] [Related]
50. IGHV mutational status testing in chronic lymphocytic leukemia.
Crombie J; Davids MS
Am J Hematol; 2017 Dec; 92(12):1393-1397. PubMed ID: 28589701
[TBL] [Abstract][Full Text] [Related]
51.
Maity PC; Bilal M; Koning MT; Young M; van Bergen CAM; Renna V; Nicolò A; Datta M; Gentner-Göbel E; Barendse RS; Somers SF; de Groen RAL; Vermaat JSP; Steinbrecher D; Schneider C; Tausch E; Bittolo T; Bomben R; Mazzarello AN; Del Poeta G; Kroes WGM; van Wezel JT; Imkeller K; Busse CE; Degano M; Bakchoul T; Schulz AR; Mei H; Ghia P; Kotta K; Stamatopoulos K; Wardemann H; Zucchetto A; Chiorazzi N; Gattei V; Stilgenbauer S; Veelken H; Jumaa H
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4320-4327. PubMed ID: 32047037
[TBL] [Abstract][Full Text] [Related]
52. Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
Bosch F; Navarro B; Crespo M; Alcoceba M; Sánchez JB; Tazón B; Serrano A; Álvarez MG; Serrano LG; Alonso-Torres P; Villanueva M; Loriente C; Abrisqueta P; Peiró M; García-Marco JA; González M; Terol MJ
Ann Hematol; 2021 Mar; 100(3):825-830. PubMed ID: 33409623
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in chronic lymphocytic leukemia.
Vyas N; Hassan A
Indian J Cancer; 2012; 49(1):137-43. PubMed ID: 22842181
[TBL] [Abstract][Full Text] [Related]
54. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia.
Irving L; Mainou-Fowler T; Parker A; Ibbotson RE; Oscier DG; Strathdee G
Epigenetics; 2011 Mar; 6(3):300-6. PubMed ID: 21051931
[TBL] [Abstract][Full Text] [Related]
55. Another step forward in the 20-year history of
Giudice ID; Foà R
Haematologica; 2019 Feb; 104(2):219-221. PubMed ID: 30705114
[No Abstract] [Full Text] [Related]
56. Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL.
Heyman B; Volkheimer AD; Weinberg JB
Blood Cancer J; 2016 Jul; 6(7):e440. PubMed ID: 27367477
[No Abstract] [Full Text] [Related]
57. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.
Van Bockstaele F; Pede V; Janssens A; Callewaert F; Offner F; Verhasselt B; Philippé J
Clin Chem; 2007 Feb; 53(2):204-12. PubMed ID: 17158192
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Factors for Chronic Lymphocytic Leukemia.
Chen C; Puvvada S
Curr Hematol Malig Rep; 2016 Feb; 11(1):37-42. PubMed ID: 26748932
[TBL] [Abstract][Full Text] [Related]
59. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
Delgado J; Salaverria I; Baumann T; Martínez-Trillos A; Lee E; Jiménez L; Navarro A; Royo C; Santacruz R; López C; Payer AR; Colado E; González M; Armengol L; Colomer D; Pinyol M; Villamor N; Aymerich M; Carrió A; Costa D; Clot G; Giné E; López-Guillermo A; Campo E; Beà S
Haematologica; 2014 Nov; 99(11):e231-4. PubMed ID: 24997154
[No Abstract] [Full Text] [Related]
60. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
